

The study entitled “A Phase III, Multicentre, Double–Blind, Placebo Controlled, Crossover Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide in the Treatment of Solar Urticaria (SU)” (CUV023) did not commence recruitment. No results can be presented.